Last Updated: August 17 2022

Berberine is a plant alkaloid with a long history of use in Ayurvedic and traditional Chinese medicine for the management of various health conditions. Its seemingly potent ability to reduce blood sugar rivals that of some anti-diabetic drugs.

Berberine is most often used for

What is berberine?

Berberine is an alkaloid found in the barks, leaves, twigs, rhizomes, roots, and/or stems of various plants, such as the barberry, Oregon grape, and tree turmeric. Traditionally, berberine has been used as an antimicrobial, antiprotozoal, and antidiarrheal agent in Ayurvedic medicine and traditional Chinese medicine. Most research in humans has examined berberine’s effects on markers of glycemic control, blood lipids, markers of liver function, and anthropometric parameters in people with metabolic disorders.

What are berberine’s main benefits?

Evidence from clinical trials conducted in people with type 2 diabetes suggests that berberine is able to reduce blood sugar to a similar extent as some anti-diabetic drugs. In people with metabolic disorders, limited research suggests that berberine may improve blood lipids and liver enzymes, and reduce body weight and fat mass. However, most of the available trials examining the effects of berberine on the aforementioned outcomes are of poor methodological quality.

What are berberine’s main drawbacks?

Although berberine appears to be generally safe in normal doses, more long-term research on its safety is needed. In some people, supplementation with berberine has been reported to cause gastrointestinal side effects, including diarrhea, constipation, flatulence, and stomach pain. Due to its ability to reduce blood sugar, berberine may increase the risk for hypoglycemia in high doses. Berberine has a high potential of interacting with a number of drugs, with some of these interactions increasing the chances of serious complications.

How does berberine work?

The main mechanism through which berberine exerts its effects appears to be the stimulation of the enzyme adenosine monophosphate-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis that is involved in a wide range of biological processes, including the regulation of glucose, lipid, and protein metabolism.

What else is Berberine known as?
Berberine should not be confused with:
  • Piperine (Black Pepper extract)
  • Berberol (Brand name)
  • Berberrubine (Metabolite)
Dosage information

The standard dose of berberine is 900-2,000mg a day, divided into three to four doses.

Berberine should be taken with a meal, or shortly after, to take advantage of the blood glucose and lipid spike associated with eating.

Too much berberine at once can result in stomach upset, cramping, and diarrhea.

Examine Database
1.^Vuddanda PR, Chakraborty S, Singh SBerberine: a potential phytochemical with multispectrum therapeutic activitiesExpert Opin Investig Drugs.(2010 Oct)
2.^Cernáková M, Kostálová DAntimicrobial activity of berberine--a constituent of Mahonia aquifoliumFolia Microbiol (Praha).(2002)
5.^Ghosh AK, Bhattacharyya FK, Ghosh DKLeishmania donovani: amastigote inhibition and mode of action of berberineExp Parasitol.(1985 Dec)
7.^Grycová L, Dostál J, Marek RQuaternary protoberberine alkaloidsPhytochemistry.(2007 Jan)
8.^Singh IP, Mahajan SBerberine and its derivatives: a patent review (2009 - 2012)Expert Opin Ther Pat.(2012 Dec 12)
9.^Krivogorsky B, Pernat JA, Douglas KA, Czerniecki NJ, Grundt PStructure-activity studies of some berberine analogs as inhibitors of Toxoplasma gondiiBioorg Med Chem Lett.(2012 Feb 22)
12.^Tillhon M, Guamán Ortiz LM, Lombardi P, Scovassi AIBerberine: new perspectives for old remediesBiochem Pharmacol.(2012 Nov 15)
13.^Wang JR, Tanaka T, Zhang H, Kouno I, Jiang ZHFormation and conformation of baicalin-berberine and wogonoside-berberine complexesChem Pharm Bull (Tokyo).(2012)
15.^Cheng Z, Chen AF, Wu F, Sheng L, Zhang HK, Gu M, Li YY, Zhang LN, Hu LH, Li JY, Li J8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse modelsBioorg Med Chem.(2010 Aug 15)
16.^Subeki, Matsuura H, Takahashi K, Yamasaki M, Yamato O, Maede Y, Katakura K, Suzuki M, Trimurningsih, Chairul, Yoshihara TAntibabesial activity of protoberberine alkaloids and 20-hydroxyecdysone from Arcangelisia flava against Babesia gibsoni in cultureJ Vet Med Sci.(2005 Feb)
17.^Schramm A, Baburin I, Hering S, Hamburger MHERG channel inhibitors in extracts of Coptidis rhizomaPlanta Med.(2011 May)
20.^Pan GY, Wang GJ, Sun JG, Huang ZJ, Zhao XC, Gu Y, Liu XDInhibitory action of berberine on glucose absorptionYao Xue Xue Bao.(2003 Dec)
21.^Maeng HJ, Yoo HJ, Kim IW, Song IS, Chung SJ, Shim CKP-glycoprotein-mediated transport of berberine across Caco-2 cell monolayersJ Pharm Sci.(2002 Dec)
22.^Chen W, Miao YQ, Fan DJ, Yang SS, Lin X, Meng LK, Tang XBioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in ratsAAPS PharmSciTech.(2011 Jun)
23.^Pan GY, Wang GJ, Liu XD, Fawcett JP, Xie YYThe involvement of P-glycoprotein in berberine absorptionPharmacol Toxicol.(2002 Oct)
24.^Chae HW, Kim IW, Jin HE, Kim DD, Chung SJ, Shim CKEffect of ion-pair formation with bile salts on the in vitro cellular transport of berberineArch Pharm Res.(2008 Jan)
26.^Qiu W, Jiang XH, Liu CX, Ju Y, Jin JXEffect of berberine on the pharmacokinetics of substrates of CYP3A and P-gpPhytother Res.(2009 Nov)
28.^Hwang YH, Cho WK, Jang D, Ha JH, Jung K, Yun HI, Ma JYEffects of berberine and hwangryunhaedok-tang on oral bioavailability and pharmacokinetics of ciprofloxacin in ratsEvid Based Complement Alternat Med.(2012)
29.^Shan YQ, Ren G, Wang YX, Pang J, Zhao ZY, Yao J, You XF, Si SY, Song DQ, Kong WJ, Jiang JDBerberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein effluxMetabolism.(2012 Oct 15)
30.^Di Pierro F, Villanova N, Agostini F, Marzocchi R, Soverini V, Marchesini GPilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic controlDiabetes Metab Syndr Obes.(2012)
33.^Zhang M, Lv X, Li J, Meng Z, Wang Q, Chang W, Li W, Chen L, Liu YSodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesisMol Cell Endocrinol.(2012 Nov 5)
36.^Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, Ren G, Ning GTreatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberineJ Clin Endocrinol Metab.(2008 Jul)
37.^Khin-Maung-U, Myo-Khin, Nyunt-Nyunt-Wai, Aye-Kyaw, Tin-UClinical trial of berberine in acute watery diarrhoeaBr Med J (Clin Res Ed).(1985 Dec 7)
40.^Wang YX, Kong WJ, Li YH, Tang S, Li Z, Li YB, Shan YQ, Bi CW, Jiang JD, Song DQSynthesis and structure-activity relationship of berberine analogues in LDLR up-regulation and AMPK activationBioorg Med Chem.(2012 Nov 15)
41.^Li Y, Ren G, Wang YX, Kong WJ, Yang P, Wang YM, Li YH, Yi H, Li ZR, Song DQ, Jiang JDBioactivities of berberine metabolites after transformation through CYP450 isoenzymesJ Transl Med.(2011 May 15)
43.^Qiu F, Zhu Z, Kang N, Piao S, Qin G, Yao XIsolation and identification of urinary metabolites of berberine in rats and humansDrug Metab Dispos.(2008 Nov)
44.^Pan JF, Yu C, Zhu DY, Zhang H, Zeng JF, Jiang SH, Ren JYIdentification of three sulfate-conjugated metabolites of berberine chloride in healthy volunteers' urine after oral administrationActa Pharmacol Sin.(2002 Jan)
47.^Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HHRepeated administration of berberine inhibits cytochromes P450 in humansEur J Clin Pharmacol.(2012 Feb)
48.^Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YYThe effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteersMethods Find Exp Clin Pharmacol.(2006 Jan-Feb)
53.^Chatuphonprasert W, Nemoto N, Sakuma T, Jarukamjorn KModulations of cytochrome P450 expression in diabetic mice by berberineChem Biol Interact.(2012 Mar 5)
54.^Cheng Q, Aleksunes LM, Manautou JE, Cherrington NJ, Scheffer GL, Yamasaki H, Slitt ALDrug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesityMol Pharm.(2008 Jan-Feb)
55.^Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli FCellular and molecular mechanisms of metformin: an overviewClin Sci (Lond).(2012 Mar)
56.^Han Y, Wang Q, Song P, Zhu Y, Zou MHRedox regulation of the AMP-activated protein kinasePLoS One.(2010 Nov 5)
57.^Cheng Z, Pang T, Gu M, Gao AH, Xie CM, Li JY, Nan FJ, Li JBerberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPKBiochim Biophys Acta.(2006 Nov)
60.^Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, Oh GT, Park HS, Lee KU, Lane MD, Kim JBBerberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activityAm J Physiol Endocrinol Metab.(2009 Apr)
61.^Brusq JM, Ancellin N, Grondin P, Guillard R, Martin S, Saintillan Y, Issandou MInhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberineJ Lipid Res.(2006 Jun)
62.^Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JDBerberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statinsNat Med.(2004 Dec)
64.^Turnley AM, Stapleton D, Mann RJ, Witters LA, Kemp BE, Bartlett PFCellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous systemJ Neurochem.(1999 Apr)
66.^Ou TM, Lu YJ, Tan JH, Huang ZS, Wong KY, Gu LQG-quadruplexes: targets in anticancer drug designChemMedChem.(2008 May)
67.^Monchaud D, Teulade-Fichou MPA hitchhiker's guide to G-quadruplex ligandsOrg Biomol Chem.(2008 Feb 21)
68.^Arora A, Balasubramanian C, Kumar N, Agrawal S, Ojha RP, Maiti SBinding of berberine to human telomeric quadruplex - spectroscopic, calorimetric and molecular modeling studiesFEBS J.(2008 Aug)
69.^Zhang WJ, Ou TM, Lu YJ, Huang YY, Wu WB, Huang ZS, Zhou JL, Wong KY, Gu LQ9-Substituted berberine derivatives as G-quadruplex stabilizing ligands in telomeric DNABioorg Med Chem.(2007 Aug 15)
76.^Hui KK, Yu JL, Chan WF, Tse EInteraction of berberine with human platelet alpha 2 adrenoceptorsLife Sci.(1991)
77.^Vizi ES, Toth I, Somogyi GT, Szabo L, Harsing LG Jr, Szantay CBerbanes: a new class of selective alpha 2-adrenoceptor antagonistsJ Med Chem.(1987 Aug)
79.^Kulkarni SK, Dhir AOn the mechanism of antidepressant-like action of berberine chlorideEur J Pharmacol.(2008 Jul 28)
81.^Kong LD, Cheng CH, Tan RXMonoamine oxidase inhibitors from rhizoma of Coptis chinensisPlanta Med.(2001 Feb)
82.^Castillo J, Hung J, Rodriguez M, Bastidas E, Laboren I, Jaimes ALED fluorescence spectroscopy for direct determination of monoamine oxidase B inactivationAnal Biochem.(2005 Aug 15)
84.^Kalalian-Moghaddam H, Baluchnejadmojarad T, Roghani M, Goshadrou F, Ronaghi AHippocampal synaptic plasticity restoration and anti-apoptotic effect underlie berberine improvement of learning and memory in streptozotocin-diabetic ratsEur J Pharmacol.(2013 Jan 5)
85.^Reisi P, Babri S, Alaei H, Sharifi MR, Mohaddes G, Noorbakhsh SM, Lashgari RTreadmill running improves long-term potentiation (LTP) defects in streptozotocin-induced diabetes at dentate gyrus in ratsPathophysiology.(2010 Feb)
88.^Bhutada P, Mundhada Y, Bansod K, Tawari S, Patil S, Dixit P, Umathe S, Mundhada DProtection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetesBehav Brain Res.(2011 Jun 20)
90.^Kulkarni SK, Dhir Asigma-1 receptors in major depression and anxietyExpert Rev Neurother.(2009 Jul)
94.^Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AEThe hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulatorScience.(2009 Feb 13)
96.^Jung HA, Min BS, Yokozawa T, Lee JH, Kim YS, Choi JSAnti-Alzheimer and antioxidant activities of Coptidis Rhizoma alkaloidsBiol Pharm Bull.(2009 Aug)
97.^Ingkaninan K, Phengpa P, Yuenyongsawad S, Khorana NAcetylcholinesterase inhibitors from Stephania venosa tuberJ Pharm Pharmacol.(2006 May)
98.^Chen XW, Di YM, Zhang J, Zhou ZW, Li CG, Zhou SFInteraction of herbal compounds with biological targets: a case study with berberineScientificWorldJournal.(2012)
99.^Asai M, Iwata N, Yoshikawa A, Aizaki Y, Ishiura S, Saido TC, Maruyama KBerberine alters the processing of Alzheimer's amyloid precursor protein to decrease Abeta secretionBiochem Biophys Res Commun.(2007 Jan 12)
102.^Marazzi G, Cacciotti L, Pelliccia F, Iaia L, Volterrani M, Caminiti G, Sposato B, Massaro R, Grieco F, Rosano GLong-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patientsAdv Ther.(2011 Dec)